Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

COVID-19: A Phase I Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of Anti-SARS-CoV-2 Monoclonal Antibody MAD0004J08 in Healthy Adults.

NCT04932850 is registered in ClinicalTrials.gov with Toscana Life Sciences Sviluppo s.r.l. as lead sponsor.

NCT NCT04932850
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04932850 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
COVID-19: A Phase I Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of Anti-SARS-CoV-2 Monoclonal Antibody MAD0004J08 in Healthy Adults.
Lead sponsor
Toscana Life Sciences Sviluppo s.r.l.
Phase
Phase 1
Overall status
Completed
Start date
March 1, 2021
Completion date
October 20, 2021
Enrollment
30 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 virus disease